Hidradenitis Suppurativa Phase 2b Study of Izokibep
A Phase 2b Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa
Sponsor: ACELYRIN Inc.
A PHASE2 clinical study on Hidradenitis Suppurativa, this trial is completed. The trial is conducted by ACELYRIN Inc. and has accumulated 21 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Completed PHASE2
-
Oct 2024 — Apr 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
▶ Show 16 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ACELYRIN Inc.
For direct contact, visit the study record on ClinicalTrials.gov .